within Pharmacolibrary.Drugs.ATC.S;

model S01BA13
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.01,
    Cl             = 0.05 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 1 / 1000000,
    adminCount     = 1,
    Vd             = 5e-05,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Rimexolone is a synthetic corticosteroid with anti-inflammatory properties, primarily used as an ophthalmic suspension to treat post-operative eye inflammation and anterior uveitis. It is an FDA-approved medication but is now less commonly used due to the availability of alternatives.</p><h4>Pharmacokinetics</h4><p>No published human pharmacokinetic (PK) data for rimexolone after ophthalmic administration could be identified; parameter estimates below are theoretical or inferred based on class and administration route.</p><h4>References</h4><ol></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end S01BA13;
